RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc. (RVP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Operations are based in Little Elm, Texas, with significant manufacturing reliance on Chinese suppliers, though the Company is shifting production domestically to mitigate tariff impacts.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: For the nine months ended September 30, 2025, net sales increased 20.2% to $28.83 million compared to $23.98 million in the prior year period. Domestic sales rose 18.0%, while international sales increased 38.1%.
• Profitability: The Company reported a net income of $0.37 million for the quarter, a significant improvement from a net loss of $1.92 million in the same quarter of 2024. However, the nine-month period resulted in a net loss of $10.22 million, compared to a loss of $15.66 million in the prior year.
• Investment Volatility: A material portion of the quarterly net income ($2.38 million) was driven by unrealized gains on debt and equity securities. Conversely, the nine-month net loss included a $3.22 million unrealized loss on these securities.
• Cost Structure: Cost of manufactured product decreased 20.1% in the quarter but increased 22.1% for the nine months, driven by higher unit sales and $1.18 million in inventory write-downs for products nearing expiration.
• Tariff Impact: Tariff expenses totaled approximately $2.3 million for the nine months ended September 30, 2025, compared to lower levels in the prior year. The prevailing tariff rate on syringe and needle products imported from China is currently 130%.

Guidance, Outlook, and Risks

• Tariff Mitigation: Management is shifting manufacturing of 1mL, 3mL, and EasyPoint needles to domestic facilities to reduce tariff exposure. This transition is expected to increase payroll costs by approximately $825,000 on an annualized basis.
• Domestic Production Expansion: The Company is adapting equipment to produce 0.5 mL syringes domestically, with commercial quantities expected in the first half of 2026. This will eliminate reliance on imports for this specific product line.
• Liquidity: The Company believes it has adequate means to fund operations for at least 12 months using cash reserves and liquidation of investments ($30.5 million). However, management expects liquidity to decline materially over the next 1-3 years due to tariffs and increased domestic manufacturing costs.
• Seasonality: Sales are expected to follow pre-pandemic seasonal patterns, with potential increases during flu season, particularly for EasyPoint products in the retail pharmacy market.
• Risks: Key risks include continued fluctuations in U.S. trade policy and tariff rates, supply chain disruptions if Chinese manufacturing is restricted, and the inability to pass increased costs to customers.

Investor Verification Checklist

• Tariff Exposure: Verify the current percentage of products sourced from China (61.7% for the first nine months of 2025) and the specific impact of the 130% tariff rate on gross margins.
• Investment Valuation: Assess the volatility of the $30.5 million investment portfolio, which significantly impacts reported net income/loss through unrealized gains and losses.
• Inventory Write-downs: Review the $1.18 million inventory write-down recorded in the first nine months of 2025 related to products nearing expiration.
• Government Contracting: Confirm the status of the Technology Investment Agreement (TIA) with the U.S. government, which provides $4.47 million in other income for the nine-month period but requires maintenance of capacity until 2030.
• Dividend Obligations: Note the $1.42 million in dividends payable, including amounts owed to former shareholders who have not yet been contacted.